SCD results of the cost structure for inpatients in the surgical group. by Chenxuan Zhu (22622476)

Subjects:

Sample hospital settlement and medication record items. by Chenxuan Zhu (22622476)

Subjects:

ITSA regression results of weekly prescription rates of NVBP varieties before and after DIP payment intervention. by Chenxuan Zhu (22622476)

Subjects:

Linear trends of the weekly total cost and cost components per capita for inpatients in the surgical group. by Chenxuan Zhu (22622476)

Subjects:

Effect of tick saliva on MDA-MB-231 cells. by Ana Carolina Prado Sousa (22265110)

Subjects:

Greene et al. raw datasets. by Justin Greene (306625)

Subjects:

Multiple bacterial subpopulations are present within splenic microcolonies. by Justin Greene (306625)

Subjects:

Droplet-based microfluidics can be used to model clustered bacterial growth. by Justin Greene (306625)

Subjects:

Acceptance of the HPV vaccine. by Mohammad Delwer Hossain Hawlader (11558838)

Subjects: “…considered statistically significant…”

Cues to the action question. by Mohammad Delwer Hossain Hawlader (11558838)

Subjects: “…considered statistically significant…”

Characteristics of the respondents (n = 2,151). by Mohammad Delwer Hossain Hawlader (11558838)

Subjects: “…considered statistically significant…”

Determinants of HPV vaccine acceptance. by Mohammad Delwer Hossain Hawlader (11558838)

Subjects: “…considered statistically significant…”

Quantification of single cell areas during MgOx treatment. by Justin Greene (306625)

Subjects:

MgOx treatment is not sufficient to alter S10 reporter activity. by Justin Greene (306625)

Subjects:

ROC Results Predicted in the Sample. by Fangyi Yang (18867853)

Subjects:

ROC Results Predicted for Out of the Sample. by Fangyi Yang (18867853)

Subjects:

Lack of T3SS expression was associated with lower S10 expression. by Justin Greene (306625)

Subjects:

T3SS induction slows growth, but cells can support high levels of S10 expression. by Justin Greene (306625)

Subjects:

Image 3_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”

Table 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.docx by Qianyi Zhou (6196383)

“…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”